Healthcare | March 11, 2023
Baxter launches the 'Choose Freedom' campaign for kidney disease patients
Chronic Kidney Disease is a growing epidemic with 850 million people affected worldwide.
Chronic Kidney Disease is a growing epidemic with 850 million people affected worldwide.
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
The kidney swap transplant procedure provides a solution to a critical shortage of compatible kidneys for patients suffering from kidney failures in India
Under this year’s theme of ‘Kidney Health For All’, ISN along with AstraZeneca aims to generate large scale awareness and educate people about ways to improve kidney health
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
Approximately five kg tumor was removed in the eight-hour long complicated surgery
The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis
Subscribe To Our Newsletter & Stay Updated
